Idiotype vaccination in follicular lymphoma: Knocking on the doorway to cure

Journal of the National Cancer Institute

Volumn 98, Issue 18, 2006, Pages 1263-1265

  Longo, Dan L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BORTEZOMIB; CANCER VACCINE; COMPLEMENTARY RNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PLACEBO; PREDNISONE; RITUXIMAB; VINCRISTINE; IMMUNOGLOBULIN IDIOTYPE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNITY; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REGRESSION; IMMUNOLOGY; NOTE; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33749009293     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj371     Document Type: Editorial

References (16)

1. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-6.
2. Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979; 90:10-3.
3. Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin's lymphoma. Cancer 1980;45:2627-32.
4. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: Results of a prospective randomized phase III intergroup trial. Blood 2006. Available at: http://www.bloodjournal.org/cgi/reprint/blood-2006-05-021113v1. [July 27 Epub ahead of print.]
5. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 1972;69: 1540-4.
6. Levy R, Dilley J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci U S A 1978;75:2411-5.
7. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517-22.
8. Raffeld M, Neckers L, Longo DL, Cossman J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. N Engl J Med 1985;312:1653-8.
9. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 1985;312:1658-65.
10. Campbell MJ, Carroll W, Kon S, Thielmans K, Rothbard JB, Levy S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987;139:2825-33.
11. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-15.
12. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
13. Timmerman JM, Vose J, Levy R, Mayo M, Denney D. Long-term follow-up of patients treated in a phase 2 trial with MyVax Personalized Immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma [abstract]. Blood 2005;106:2438.
14. Inogès S, Rodríguez-Calvillo M, Zabalgui N, López-Díaz de Cerio A, Villanueva H, Soria E, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006; 98:1292-301.
15. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 1995;13:140-7.
16. Caspar CB, Levy S, Levy R. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 1997;90:3699-706.